Ligand validation:4L8F

MTX: METHOTREXATE

MTX is a Ligand Of Interest in 4L8F designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4L8F_MTX_D_301	28%	9%	0.216	0.868	2.27	2.36	6	14	11	0	100%	1
4L8F_MTX_B_301	15%	9%	0.269	0.832	2.39	2.23	7	14	10	0	100%	1
4L8W_MTX_I_301	17%	12%	0.205	0.784	1.89	2.34	5	14	1	0	97%	0.9697
1RA3_MTX_A_161	97%	10%	0.058	0.974	1.61	2.84	8	23	1	0	100%	1
1U72_MTX_A_188	97%	24%	0.065	0.979	0.9	2.35	-	13	2	0	100%	1
1RG7_MTX_A_161	94%	8%	0.071	0.968	1.88	2.93	9	17	1	0	100%	1
1DDR_MTX_B_200	93%	2%	0.077	0.971	2.29	4.49	7	20	0	1	100%	1
3IA4_MTX_A_164	91%	15%	0.077	0.962	2.08	1.91	4	9	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.